JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2007; 49:27-28, doi:10.1016/S0735-1097(07)00251-3
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

INSIDE THIS ISSUE OF JACC

Inside This Issue of JACC


   Interventional Cardiology
Top
 Interventional Cardiology
Heart Failure
 Heart Failure
 Preclinical Study
 
Frequent Post-PCI Events in Poor Responders to Clopidogrel.  
Figure 1
Multiple studies have shown that the magnitude of the response to clopidogrel is variable, but the clinical significance of this finding remains uncertain. Bliden and colleagues measured pre-percutaneous coronary intervention (PCI) platelet aggregation in patients on chronic clopidogrel who were followed for 1 year. Their criteria identified 22% of patients as nonresponders who were 30 times more likely to suffer a subsequent event, with higher risk in both the first 30 days and the subsequent 11 months. This study suggests that measuring the effectiveness of clopidogrel-induced platelet inhibition identifies patients at increased risk for post-PCI ischemic complications. See page 657. See figure.


   Heart Failure
Top
 Interventional Cardiology
 Heart Failure
Heart Failure
 Preclinical Study
 
Ultrafiltration Reduces Rehospitalization for CHF.   Ultrafiltration is an emerging alternative to loop diuretics for patients with fluid overload. Costanzo and colleagues performed a randomized, multicenter trial comparing ultrafiltration with standard diuretic therapy in 200 heart failure patients admitted with volume overload. At 48 h, weight loss and net fluid loss were both significantly greater in the ultrafiltration group, though symptoms of CHF improved similarly in both groups. Adverse event rates were similar. Subjects treated with ultrafiltration were 44% less likely to be rehospitalized over the next 90 days. These data indicate that in decompensated heart failure, ultrafiltration safely produces greater fluid loss than intravenous diuretics over the first 48 h, and may have sustained benefits over the next 90 days. See page 675.


   Heart Failure
Top
 Interventional Cardiology
 Heart Failure
 Heart Failure
Preclinical Study
 
Severity of Diastolic Dysfunction Predicts Outcomes.  
Figure 2
There is limited evidence regarding the significance of echo evidence of diastolic dysfunction (DD) in predicting outcomes in patients with HF and preserved systolic function (HF-PSF). Persson and colleagues examined echo and BNP results in over 300 patients enrolled in the CHARM Preserved Study. DD was found in 67% of study subjects, pseudonormal or restrictive filling in 44%. Over the next 18 months, death or readmission for heart failure correlated strongly with the severity of DD. These results demonstrate the prognostic significance of echo DD in HF-PSF patients, and suggest that an elevated BNP may be a reliable method for distinguishing normal from pseudo-normal filling patterns. See page 687. See figure.


   Preclinical Study
Top
 Interventional Cardiology
 Heart Failure
 Heart Failure
 Preclinical Study
 
Everolimus-Eluting Stents May Stabilize Plaques.  
Figure 3
Macrophages in atherosclerotic plaques are known to secrete proteolytic enzymes that can lead to rupture of the fibrous cap. Verheye and colleagues studied the effects of everolimus on the composition of atherosclerotic plaques. The first experiment involved placing both control stents and everolimus coated stents in rabbit aortas, which demonstrated that everolimus reduced the number of macrophages over the next 4 weeks. Further studies confirmed that everolimus, by inhibiting the mammalian target of rapamycin (mTOR) protein, resulted in programmed cell death in macrophages but not smooth muscle cells. Stent-based delivery of an mTOR inhibitor appears to be a promising method to selectively remove macrophages from atherosclerotic plaques and thereby improve plaque stability. See page 706. See figure.





This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK